Relapse Rates, Time-to-Flare, and Biomarker Predictors Following Omalizumab Gradual De-escalation versus Abrupt Discontinuation in Controlled Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Cohorts.